Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults

Objective: Since Alzheimer disease (AD) neuropathology is thought to develop years before dementia, it may be possible to detect subtle AD-related atrophy in preclinical AD. Here we hypothesized that the “disease signature” of AD-related cortical thinning, previously identified in patients with mild AD dementia, would be useful as a biomarker to detect anatomic abnormalities consistent with AD in cognitively normal (CN) adults who develop AD dementia after longitudinal follow-up. Methods: We studied 2 independent samples of adults who were CN when scanned. In sample 1, 8 individuals developing AD dementia (CN-AD converters) after an average of 11.1 years were compared to 25 individuals who remained CN (CN-stable). In sample 2, 7 CN-AD converters (average follow-up 7.1 years) were compared to 25 CN-stable individuals. Results: AD-signature cortical thinning in CN-AD converters in both samples was remarkably similar, about 0.2 mm (p < 0.05). Despite this small absolute difference, Cohen d effect sizes for these differences were very large (>1). Of the 11 CN individuals with baseline low AD-signature thickness (≥1 SD below cohort mean), 55% developed AD dementia over nearly the next decade, while none of the 9 high AD-signature thickness individuals (≥1 SD above mean) developed dementia. This marker predicted time to diagnosis of dementia (hazard ratio = 3.4, p < 0.0005); 1 SD of thinning increased dementia risk by 3.4. Conclusions: By focusing on cortical regions known to be affected in AD dementia, subtle but reliable atrophy is identifiable in asymptomatic individuals nearly a decade before dementia, making this measure a potentially important imaging biomarker of early neurodegeneration.

[1]  J. Kaye,et al.  Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia , 1997, Neurology.

[2]  Keith A. Johnson,et al.  Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.

[3]  Rachel L. Mistur,et al.  Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal , 2010, Neurobiology of Aging.

[4]  J. Lindeboom,et al.  Subjective memory complaints may announce dementia , 1996, Neurology.

[5]  Karl J. Friston,et al.  Automatic Differentiation of Anatomical Patterns in the Human Brain: Validation with Studies of Degenerative Dementias , 2002, NeuroImage.

[6]  M. Mintun,et al.  Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. , 2008, Archives of neurology.

[7]  Michael I. Miller,et al.  Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly , 2005, NeuroImage.

[8]  S. Leurgans,et al.  MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD , 2004, Neurobiology of Aging.

[9]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[10]  Charles D. Smith,et al.  Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment , 2010, Neurobiology of Aging.

[11]  A. Hofman,et al.  Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. , 2006, Archives of general psychiatry.

[12]  Y. Stern Cognitive Reserve and Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[13]  Nick C Fox,et al.  Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images , 2001, The Lancet.

[14]  Alistair Burns,et al.  Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356 , 1997 .

[15]  F. Schmitt,et al.  Brain structural alterations before mild cognitive impairment , 2007, Neurology.

[16]  J. Morris,et al.  Longitudinal study of the transition from healthy aging to Alzheimer disease. , 2009, Archives of neurology.

[17]  Anders M. Dale,et al.  Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls , 2010, NeuroImage.

[18]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[19]  A. Saykin,et al.  Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI , 2006, Neurology.

[20]  H. Fathallah-Shaykh Malignant astrocytomas: a system disease. , 2010, Archives of neurology.

[21]  Nick C Fox,et al.  Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. , 1996, Brain : a journal of neurology.

[22]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[24]  M. Roth,et al.  Observations on the brains of non-demented old people. , 1968, Journal of the neurological sciences.

[25]  J. Kaye,et al.  Cognitive Markers Preceding Alzheimer's Dementia in the Healthy Oldest Old , 1997, Journal of the American Geriatrics Society.

[26]  Nick C Fox,et al.  Assessing the onset of structural change in familial Alzheimer's disease , 2003, Annals of neurology.

[27]  B. Hyman,et al.  The Lack of Accumulation of Senile Plaques or Amyloid Burden in Alzheimer's Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution , 1993, Journal of neuropathology and experimental neurology.

[28]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[29]  L. Wolfson,et al.  Clinico‐pathologic studies in dementia , 1988, Neurology.

[30]  J. Miller,et al.  A prospective study of cognitive function and onset of dementia in cognitively healthy elders. , 1998, Archives of neurology.

[31]  Peter Davies,et al.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans , 1992, Neurobiology of Aging.

[32]  R. Woods,et al.  Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. , 2001, Cerebral cortex.

[33]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[34]  R. Lipton,et al.  Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease , 2008, Journal of the International Neuropsychological Society.

[35]  H. Amièva,et al.  Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms , 2008, Annals of neurology.

[36]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[37]  W. Markesbery,et al.  Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease , 2004, Neurology.

[38]  André J. W. van der Kouwe,et al.  Detection of cortical thickness correlates of cognitive performance: Reliability across MRI scan sessions, scanners, and field strengths , 2008, NeuroImage.

[39]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[40]  C B Hall,et al.  A change point model for estimating the onset of cognitive decline in preclinical Alzheimer's disease. , 2000, Statistics in medicine.

[41]  M. Albert,et al.  Neuropsychological measures in normal individuals that predict subsequent cognitive decline. , 2007, Archives of neurology.

[42]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[43]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[44]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .